Treatment and prophylaxis of amyloidosis
AssigneesElan Pharmaceuticals, Inc., University of Tennessee Research Foundation
InventorsDale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha
Life of this patent
Estimating the term…
Abstract
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
Claims4
1-90. (canceled)
An isolated human, humanized, or chimeric antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within residues 70-76 of human amyloid A peptide, wherein the antibody or antigen-binding fragment thereof competes for binding to human amyloid A peptide with antibody 2A4 produced by ATCC Accession Number PTA-9662.
Dependencies are inferred from the claim text.